TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8199787

Group type: EXPERIMENTAL
Intervention: Subtypes of major depression classified by longitudinal course
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indicators of validity for recurrent depression
Number of subjects: 0
Study: 3148366

Group type: EXPERIMENTAL
Intervention: Orally administered thyrotropin-releasing hormone (TRH) (40 mg/day for 10 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29685026

Group type: EXPERIMENTAL
Intervention: Biophysical therapy using a Med Select 729 device
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ibuprofen (non-steroidal anti-inflammatory drug)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 26699917

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VAP (as a time-dependent covariate)
Number of subjects: 0
Study: 25234648

Group type: EXPERIMENTAL
Intervention: Elosulfase alfa at 2.0 mg/kg administered weekly for 24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elosulfase alfa at 2.0 mg/kg administered every other week for 24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly dosing cohort
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both dosing cohorts
Number of subjects: 0
Study: 23261008

Group type: EXPERIMENTAL
Intervention: PSYMEPHY (interdisciplinary treatment, 12 sessions)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Standard pharmacologic therapy (control group)
Number of subjects: 153
Study: 20538493

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 18690162

Group type: EXPERIMENTAL
Intervention: tesamorelin 2 mg
Number of subjects: 273

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 273
Study: 17006977

Group type: EXPERIMENTAL
Intervention: Prophylactic polypropylene mesh (n = 36)
Number of subjects: 74

Group type: COMPARATOR
Intervention: No polypropylene mesh (n = 38)
Number of subjects: 74
Study: 14530468

Group type: EXPERIMENTAL
Intervention: (99m)Tc‐MIBI SPECT
Number of subjects: 29
Study: 10746426

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once-weekly
Number of subjects: 1258

Group type: EXPERIMENTAL
Intervention: Alendronate 35 mg twice-weekly
Number of subjects: 1258

Group type: COMPARATOR
Intervention: Alendronate 10 mg daily
Number of subjects: 1258

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1258

Group type: EXPERIMENTAL
Intervention: Once-weekly dosing group
Number of subjects: 1258
Study: 8636828

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (1500 micrograms of beclomethasone via spacer for 30 days)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard treatment without inhaled corticosteroids
Number of subjects: 49
Study: 1609941

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 30
Study: 4054524

Group type: EXPERIMENTAL
Intervention: Polycose meal volume of 300 ml
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Polycose meal energy density of 0.7 kcal/ml
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Overall mean rate of caloric emptying
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Initial 30 min period
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Increased meal volume or energy density
Number of subjects: 21
Study: 31895638

Group type: EXPERIMENTAL
Intervention: Perfluorohexyloctane eye drops
Number of subjects: 48

Group type: COMPARATOR
Intervention: Unpreserved 0.9% saline solution (Hydrabak®) eye drops
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 48
Study: 29976109

Group type: EXPERIMENTAL
Intervention: Theoretical narrative medicine education for 1 term (Group 2)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Narrative medicine education integrating theory with practice for 2 terms (Group 3)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Regular medical education courses (Group 1)
Number of subjects: 180
Study: 27515419

Group type: EXPERIMENTAL
Intervention: cilnidipine (N/L type CCB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: amlodipine (L type CCB)
Number of subjects: 60
Study: 24573731

Group type: EXPERIMENTAL
Intervention: L-menthol (20 mL of 1.6% L-menthol)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study: 22541143

Group type: COMPARATOR
Intervention: Primary Closure (PC)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Delayed Primary Closure (DPC)
Number of subjects: 70
Study: 20213833

Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18478333

Group type: EXPERIMENTAL
Intervention: Family Communications (FC) activities
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Youth Anti‐tobacco Activities (YAT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 40
Study: 15829018

Group type: EXPERIMENTAL
Intervention: Zafirlukast (leucotriene antagonist) for four weeks, along with doxycycline
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo for four weeks, along with doxycycline
Number of subjects: 17
Study: 12005317

Group type: EXPERIMENTAL
Intervention: Methylphenidate (5 to 15 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (NF1 without ADHD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (ADHD without NF1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (normally developing children)
Number of subjects: 20
Study: 11199824

Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser treatment at cervical regions with black ink
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser treatment at cervical regions without black ink
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser treatment at apical regions with black ink
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser treatment at apical regions without black ink
Number of subjects: 54
Study: 8705220

Group type: EXPERIMENTAL
Intervention: 400 mg of norfloxacin twice daily for one week
Number of subjects: 491

Group type: COMPARATOR
Intervention: 400 mg of norfloxacin twice daily for one day
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: 400 mg of norfloxacin twice daily for one week (in patients with risk factors)
Number of subjects: 491

Group type: COMPARATOR
Intervention: 400 mg of norfloxacin twice daily for one day (in patients with risk factors)
Number of subjects: 491
Study: 1846868

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH-a) alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combined CEE and MPA with GnRH-a
Number of subjects: 8

Group type: COMPARATOR
Intervention: CEE alone
Number of subjects: 8

Group type: COMPARATOR
Intervention: MPA alone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6357043

Group type: EXPERIMENTAL
Intervention: Diltiazem (180 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30862556

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional restorative technique (CT)
Number of subjects: 99
Study: 29448259

Group type: EXPERIMENTAL
Intervention: Rotating needles device (RND)
Number of subjects: 34
Study: 27488212

Group type: EXPERIMENTAL
Intervention: TAU + CBT4CBT
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: CBT4CBT + monitoring
Number of subjects: 68

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: All CBT4CBT conditions
Number of subjects: 68
Study: 24696507

Group type: EXPERIMENTAL
Intervention: PF‐04494700 60 mg/day × 6 days, then 20 mg daily (high dose)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: PF‐04494700 15 mg/day × 6 days, then 5 mg daily (low dose)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study: 22530777

Group type: EXPERIMENTAL
Intervention: Replica running shoes
Number of subjects: 12

Group type: COMPARATOR
Intervention: Original running shoes
Number of subjects: 12
Study: 20203165

Group type: EXPERIMENTAL
Intervention: High‐flux polyamide membrane
Number of subjects: 46

Group type: COMPARATOR
Intervention: Low‐flux polyamide membrane
Number of subjects: 46
Study: 17608154

Group type: EXPERIMENTAL
Intervention: MUPPP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (non-OSAHS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated group (10 patients)
Number of subjects: 30
Study: 15297165

Group type: EXPERIMENTAL
Intervention: 4‐HPR (200 mg/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 11270943

Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zafirlukast 40 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zafirlukast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaled fluticasone propionate 88 microg or salmeterol 42 microg
Number of subjects: 0
Study: 9840560

Group type: EXPERIMENTAL
Intervention: Local infiltration of 0.5% bupivacaine before incision (Treatment group A)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Saline placebo before skin incision and bupivacaine after laparoscopy (Treatment group B)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Saline placebo before and after laparoscopy (Treatment group C)
Number of subjects: 57
Study: 8206772

Group type: EXPERIMENTAL
Intervention: Videotaped procedural modeling information
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Videotaped procedural-sensory modeling information
Number of subjects: 145

Group type: COMPARATOR
Intervention: Procedural-sensory information booklet
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: All three preparatory informational treatments
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Self-reported anxiety (SUDS)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Physiologic measures (heart rate and blood pressure)
Number of subjects: 145
Study: 2648645

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms by inhalation)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Platelet activating factor
Number of subjects: 7
Study: 30882244

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum DR7 (1×10^9 cfu/day) for 12 weeks
Number of subjects: 111
Study: 28838366

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 25223696

Group type: EXPERIMENTAL
Intervention: 100% (w/w) fructose (F100)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 90% fructose+10% glucose (F90G10)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 55% fructose+45% glucose (F55G45)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 100% glucose (G100)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: F100 and F90G10
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: F100
Number of subjects: 12
Study: 23965191

Group type: EXPERIMENTAL
Intervention: TAP block (local anesthetic)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2
Study: 21799444

Group type: EXPERIMENTAL
Intervention: Albuminuria (normal range)
Number of subjects: 540

Group type: COMPARATOR
Intervention: eGFR
Number of subjects: 540
Study: 19451431

Group type: EXPERIMENTAL
Intervention: FOLFOX4 (oxaliplatin, fluorouracil, and leucovorin)
Number of subjects: 2246

Group type: COMPARATOR
Intervention: LV5FU2 (fluorouracil and leucovorin)
Number of subjects: 2246
Study: 16060912

Group type: COMPARATOR
Intervention: GnRHa alone (Group A)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: GnRHa with GH (Group B)
Number of subjects: 26
Study: 10599554

Group type: EXPERIMENTAL
Intervention: Tibolone + fluoride (2.5 mg of tibolone + 26.4 mg of fluoride daily for 2 years)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo + fluoride (placebo + 26.4 mg of fluoride daily for 2 years)
Number of subjects: 94
Study: 8541006

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 6797
Study: 2024543

Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 to 40 mg daily, mean 18.3 mg)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 253
Study: 6168856

Group type: EXPERIMENTAL
Intervention: 0.5 mg digitoxin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1.0 mg digitoxin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1.0 mg digoxin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31788233

Group type: EXPERIMENTAL
Intervention: ICT-CCS intervention
Number of subjects: 4100
Study: 30295536

Group type: COMPARATOR
Intervention: Nonoperative treatment with a sling
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Fixation with a pre‐contoured plate and locking screws
Number of subjects: 146
Study: 26975533

Group type: EXPERIMENTAL
Intervention: Severe energy deficit (ED; 3681±716 kcal/d energy deficit)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Energy balance (EB; 36±93 kcal/d energy deficit)
Number of subjects: 23
Study: 24472398

Group type: EXPERIMENTAL
Intervention: 8 mg OROS hydromorphone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 16 mg OROS hydromorphone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 32 mg OROS hydromorphone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 64 mg OROS hydromorphone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 50 mg naltrexone (concomitant with hydromorphone)
Number of subjects: 23
Study: 22496918

Group type: EXPERIMENTAL
Intervention: Continuously abstinent (biochemically confirmed abstinence at 6 months, 1 year, and 3 years post-quit attempt)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Smoked continuously (reported smoking at all three time points)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Intermittently abstinent (reported smoking at one of the three time points)
Number of subjects: 795
Study: 20639832

Group type: EXPERIMENTAL
Intervention: Parenteral amino acid (5%) supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual nutritional management (10% intravenous dextrose and subsequent enteral feeding)
Number of subjects: 60
Study: 17931979

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose then 75 mg daily)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo (for clopidogrel)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo (for simvastatin)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 392
Study: 15821100

Group type: EXPERIMENTAL
Intervention: SFA diet (38% fat: 20% SFA, 12% MUFA, 6% PUFA)
Number of subjects: 59

Group type: COMPARATOR
Intervention: CHO diet (<10% SFA, 12% MUFA, 6% PUFA)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Mediterranean diet (<10% SFA, 22% MUFA, 6% PUFA)
Number of subjects: 59
Study: 11909567

Group type: EXPERIMENTAL
Intervention: High serum lipoprotein(a) (≥20 mg/dl) and high low-density lipoprotein (LDL) cholesterol (≥3.63 mmol/L [≥140 mg/dl])
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: High serum lipoprotein(a) (≥20 mg/dl) and high low-density lipoprotein (LDL) cholesterol (≥3.63 mmol/L [≥140 mg/dl]) combined with type 2 diabetes mellitus
Number of subjects: 400
Study: 9817951

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (part of a multidisciplinary treatment package)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no cognitive behavioural therapy)
Number of subjects: 22
Study: 9638201

Group type: EXPERIMENTAL
Intervention: Boys with lipid risk factors for atherosclerosis
Number of subjects: 45

Group type: COMPARATOR
Intervention: Boys without lipid risk factors for atherosclerosis (Control)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Increased serum cholesterol level
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Decreased serum HDL-cholesterol concentration
Number of subjects: 45
Study: 2695151

Group type: EXPERIMENTAL
Intervention: Bromocriptine (5 mg/day for three months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31285667

Group type: EXPERIMENTAL
Intervention: E-mail messages with problem-solving content
Number of subjects: 5449
Study: 29100550

Group type: EXPERIMENTAL
Intervention: LPG stoves and fuel distribution
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group receiving LPG stoves and vouchers for free fuel
Number of subjects: 180
Study: 25511685

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 0
Study: 24054380

Group type: EXPERIMENTAL
Intervention: Polypropylene mesh (PM) implant
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional anterior vaginal wall colporraphy (Control)
Number of subjects: 100
Study: 20646849

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (RT)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Cranially reduced clinical target volume (CTV) to the S2-S3 interspace
Number of subjects: 94

Group type: COMPARATOR
Intervention: No primary nodal involvement and negative circumferential resection margin (CRM)
Number of subjects: 94
Study: 20663491

Group type: EXPERIMENTAL
Intervention: Worry Exposure (WE)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Audio-Photic Stimulation (APS)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Expressive Writing (EW)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: All treatment conditions
Number of subjects: 113
Study: 17175561

Group type: EXPERIMENTAL
Intervention: CareFile booklet (intervention group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual stroke information leaflets (control group)
Number of subjects: 100
Study: 15785218

Group type: EXPERIMENTAL
Intervention: GSM mobile telephone short-message service (SMS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 12360156

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) therapy with GP IIb/IIIa receptor antagonists
Number of subjects: 0
Study: 9469979

Group type: EXPERIMENTAL
Intervention: Radiosensitizer tablets Nimorazol given 1 1/2 hours before radiation, six fractions weekly for patients with squamous cell cancer in the supraglottic region, pharynx and oral cavity.
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (specific details not provided).
Number of subjects: 1800
Study: 7658328

Group type: EXPERIMENTAL
Intervention: rhEPO
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2665110

Group type: EXPERIMENTAL
Intervention: Arthritis Self‐management Course (ASMC) + bi‐monthly arthritis newsletter
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Arthritis Self‐management Course (ASMC) + 6-week Arthritis Reinforcement Course (ARC)
Number of subjects: 589

Group type: COMPARATOR
Intervention: Arthritis Self‐management Course (ASMC) + no reinforcement
Number of subjects: 589
Study: 141020

Group type: EXPERIMENTAL
Intervention: Meridian loci needling (MLN)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tender area needling (TAN)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy after subarachnoid injection of 0.25% procaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy after 1% procaine sensory and motor blockade
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Differential spinal block (DSB)
Number of subjects: 40
Study: 30669914

Group type: EXPERIMENTAL
Intervention: Airway clearance techniques (ACTs)
Number of subjects: 7
Study: 30958058

Group type: EXPERIMENTAL
Intervention: External Counterpulsation (ECP)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 27264267

Group type: EXPERIMENTAL
Intervention: Docetaxel plus gemcitabine (DG) - docetaxel 30 mg/m2 plus gemcitabine 900 mg/m2 i.v. on days 1 and 8, every 3 weeks
Number of subjects: 106

Group type: COMPARATOR
Intervention: Gemcitabine (G) - gemcitabine 1200 mg/m2 i.v. on days 1 and 8, every 3 weeks
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Instrumental Activities of Daily Living (IADL) score < 7
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Instrumental Activities of Daily Living (IADL) score ≥ 7
Number of subjects: 106
Study: 26002805

Group type: COMPARATOR
Intervention: Cupid2 female condom
Number of subjects: 300

Group type: COMPARATOR
Intervention: Velvet female condom
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: FC2 female condom
Number of subjects: 300

Group type: COMPARATOR
Intervention: All female condoms
Number of subjects: 300
Study: 24483110

Group type: EXPERIMENTAL
Intervention: Jianbu Tongluo Xunzheng Liquid (JTXL), fumigated for 30 min once daily for 10 times (3 courses total)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Combination of JTXL fumigation and Sodium Hyaluronate Injection (SHI), 3 mL each time, once per 6 days for 5 times
Number of subjects: 105

Group type: COMPARATOR
Intervention: Sodium Hyaluronate Injection (SHI), 3 mL each time, once per 6 days for 5 times
Number of subjects: 105
Study: 21222114

Group type: EXPERIMENTAL
Intervention: Trans-obturator tape (TOT; Monarc, American Medical Systems)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Trans-vaginal tape (TVT; Gynecare)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both TOT and TVT
Number of subjects: 114
Study: 19839536

Group type: EXPERIMENTAL
Intervention: Cluster randomisation in interventional studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cluster randomisation
Number of subjects: 0